BioLineRx Stock Volatility
| BLRX Stock | USD 3.10 -0.25 -7.46% |
Sharpe Ratio = 0.0359
Expected Return ↓
Minimal
Low
Moderate
Elevated
High
Leading
Strong
Moderate
Modest
Flat
Below
Ideal
BLRX
Worst
← Lower RiskHigher Risk →
BioLineRx reported a Market Risk Adjusted Performance of -1.3%, a Risk of 4.74, and a Risk Adjusted Performance of 0.04%. Monthly moving average analysis places it at roughly 2% of its prior performance bandwidth.
Key indicators related to BioLineRx's volatility include:90 Days Market Risk | Chance Of Distress | 90 Days Economic Sensitivity |
Key risk metrics for BioLineRx (3 Months):
Beta -0.12 | Alpha 0.16 | Risk 4.74 | Sharpe Ratio 0.04 | Expected Return 0.17 |
Moving together with BioLineRx Stock
Moving Against BioLineRx Stock
| 0.56 | JRFIF | Japan Metropolitan | PairCorr |
| 0.53 | CVX | Chevron Corp | PairCorr |
| 0.49 | XOM | Exxon Mobil Corp | PairCorr |
| 0.46 | PFE | Pfizer Inc Sell-off Trend | PairCorr |
Sensitivity To Market
BioLineRx beta of -0.12 quantifies how much of its total volatility (4.74%) is attributable to market-wide factors versus idiosyncratic drivers. BioLineRx return dispersion over the lookback window shows standard deviation near 4.74% and semi-deviation near 4.07%, providing a baseline for comparison across peer instruments. Stock volatility reflects changes in expectations about revenue, margins, and competitive position. For BioLineRx, price swings may be influenced by sector movement and company-specific headlines.
3 Months Beta |BioLineRx Demand TrendCurrent 90-day BioLineRx correlation with market (Dow Jones Industrial)Downside Risk
BioLineRx daily return dispersion, captured by standard deviation, sets the baseline volatility reading for this instrument. High standard deviation indicates a volatile instrument; low standard deviation indicates a more stable one. Shifting the lookback window for BioLineRx reveals whether current dispersion is consistent with its longer-term pattern. Changes in BioLineRx standard deviation over successive periods may signal shifts in the underlying return regime.
Standard Deviation | 4.74 |
An important distinction for BioLineRx is between total volatility and downside-only risk. Downside deviation and semi-deviation isolate the loss risk in BioLineRx's daily returns from favorable moves. Total dispersion for BioLineRx captures both favorable and adverse price swings. Downside deviation focuses exclusively on the adverse side of BioLineRx's return distribution. BioLineRx reported a Downside Deviation of 4.47, a Downside Variance of 20.00, and a Maximum Drawdown of 28.36.
Stock Volatility Analysis
Tracking BioLineRx volatility quantifies the degree of price uncertainty over a given period. Highly volatile stocks like BioLineRx tend to experience wider price swings in both directions. Periods of high volatility for BioLineRx present both elevated risk and wider price ranges for traders. When BioLineRx experiences high volatility, its stock price shifts dramatically in a short period.
Transformation |
This analysis covers sixty-one data points across the selected time horizon. The Average Price transformation calculates the mean of BioLineRx's open, high, low, and close for each trading period. By incorporating all four price components equally, it provides a balanced representation of each period's trading activity. Compared to using the closing price alone, the average price reduces the influence of end-of-day positioning and can serve as a smoother input for other technical indicators.
Projected Return Density Against Market
Given a 90-day horizon, BioLineRx has a beta of -0.1234 suggesting that as returns on the benchmark increase, returns on BioLineRx tend to move in the opposite direction, though by a smaller magnitude. During a bear market, however, BioLineRx tends to outperform the market.Market risk ties BioLineRx to macro cycles, whereas company or sector-specific developments represent independent drivers. Volatility metrics help measure this balance. BioLineRx reported a Downside Deviation of 4.47, a Mean Deviation of 3.00, and a Semi Deviation of 4.07.
Predicted Return Distribution |
| Density |
What Drives BioLineRx's Price Volatility?
Industry Dynamics
Sector-level catalysts in the Biotechnology sector often set the baseline volatility regime for BioLineRx.Political and Economic Environment
Interest-rate path changes, geopolitical developments, and macro surprises influence investor risk tolerance.BioLineRx's Company-Specific Factors
Execution updates, margin trends, and corporate actions can shift near-term return dispersion for BioLineRx's.Stock Risk Measures
Given a 90-day horizon, the coefficient of variation of BioLineRx is 2787.27. The daily returns are distributed with a variance of 22.46 and standard deviation of 4.74. The mean deviation of BioLineRx is currently at 3.0. For similar time horizon, the selected benchmark (Dow Jones Industrial) has volatility of 0.97
α | Alpha over Dow Jones | 0.16 | |
β | Beta against Dow Jones | -0.1234 | |
σ | Overall volatility | 4.74 | |
Ir | Information ratio | 0.03 |
Stock Return Volatility
BioLineRx daily volatility tracks how widely stock returns have moved around the mean across the selected time frame. The company reflects 4.7396% volatility on return distribution over a 90-day horizon. On the other hand, Dow Jones Industrial reported 0.9238% volatility on return distribution over a 90-day investment horizon. Performance |
| Timeline |
Related Correlations Analysis
Please upgrade your account to get full access to Macroaxis premium features
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Return momentum in BioLineRx Stock is more useful when tested against peer-relative fundamentals and risk. Reviewing BioLineRx's risk-adjusted indicators gives a clearer view of whether returns are being earned efficiently. These indicators are quantitative in nature and measure volatility and risk-adjusted expected returns across different positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| THAR | 3.99 | -0.31 | 0.00 | -0.50 | 0.00 | 6.77 | 20.99 | |||
| GOVX | 4.52 | -0.55 | 0.00 | -0.80 | 0.00 | 9.48 | 29.15 | |||
| ADAP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| APLM | 2.98 | -0.21 | 0.00 | 1.11 | 0.00 | 5.92 | 29.52 | |||
| ANL | 5.31 | 0.76 | 0.12 | 0.27 | 5.45 | 15.78 | 45.51 | |||
| ADTX | 6.71 | -5.35 | 0.00 | -3.30 | 0.00 | 7.69 | 54.05 | |||
| MBRX | 3.67 | -0.59 | 0.00 | -0.46 | 0.00 | 5.48 | 49.77 | |||
| AIMD | 3.63 | -0.03 | 0.00 | -0.01 | 0.00 | 8.84 | 27.81 | |||
| ICU | 4.89 | 1.26 | 0.27 | 1.01 | 4.06 | 13.48 | 43.04 | |||
| LNAI | 11.91 | 0.80 | 0.07 | 0.48 | 10.76 | 25.76 | 195.24 |
Risk Metrics, Assumptions & Methodology
Standard deviation for BioLineRx measures how widely returns scatter around their average over a given period. Dispersion compression can indicate low-information regimes where prices drift on thin conviction. BioLineRx has a market cap of 13.68 million, ROE of -11.01%.
BioLineRx inputs come from periodic company reporting and market reference feeds and are mapped into a consistent reporting framework. Volatility and downside metrics are estimated from historical return dispersion.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board
Volatility Profile Summary
Recent data suggests that BioLineRx is more volatile than Dow Jones Industrial by approximately 5.15x over the selected horizon. This differential reflects the relative dispersion of returns and frames how the asset responds to broader market conditions. Observed price behavior indicates modest directional movement within the current volatility regime. Across the current 90-day horizon, that places the security below 42% of the broader equity and portfolio universe on a pure volatility basis. This positioning reflects relative dispersion compared to peers rather than extreme instability.BioLineRx exhibits characteristics that tend to dampen sensitivity to smaller market fluctuations within the current volatility regime. This price-change note interprets the latest move in the context of short-horizon trading behavior. It gains reliability when combined with broader risk controls and volatility-adjusted analysis. a very speculative upward sentiment. Return distributions derived from historical modeling outline a range of potential outcomes over the selected 90-day horizon. View BioLineRx probability analysis.
Weak diversification
For the present investment horizon, the measured correlation between BioLineRx and Dow Jones stands at 0.54, or Weak diversification. In portfolio terms, the overlap shows how much shared movement remains after combining both positions.
Additional Risk Indicators
Risk analysis around BioLineRx gains depth when secondary indicators confirm, refine, or challenge the basic volatility picture. Cross-security comparison within similar growth and valuation profiles provides additional context for interpreting relative risk positioning.
| Risk Adjusted Performance | 0.0426 | |||
| Market Risk Adjusted Performance | -1.29 | |||
| Mean Deviation | 3.0 | |||
| Semi Deviation | 4.07 | |||
| Downside Deviation | 4.47 | |||
| Coefficient Of Variation | 2787.27 | |||
| Standard Deviation | 4.74 |
BioLineRx Suggested Diversification Pairs
Pair analysis provides a framework for evaluating relative performance between BioLineRx and comparable securities. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Pair strategies reduce risk, but not all risk is diversifiable through pairing. Market-level risk for BioLineRx persists even in a well-constructed pair. The benefit is in offsetting BioLineRx's company-specific risk, which can be meaningfully reduced by selecting a second position that moves independently of BioLineRx.
Popular Tools for BioLineRx Stock analysis
Pattern RecognitionUse different Pattern Recognition models to identify potential trend changes across multiple global exchangesCommodity ChannelUse Commodity Channel Index to analyze current equity momentumInsider ScreenerFind insiders across different sectors to evaluate their impact on performanceCEOs DirectoryScreen CEOs from public companies around the worldPortfolio ProphetUse AI to generate optimal portfolios and find investment opportunities